Viking Therapeutics, Inc.
A clinical-stage biopharmaceutical company in San Diego that develops experimental drugs for metabolic and endocrine disorders, including obesity. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being tested as both a weekly injection and a daily pill for weight loss. Founded in 2012 by Brian Lian, a former Wall Street biotech analyst, the company built its early pipeline by licensing programs from Ligand Pharmaceuticals.
Granted 2.22M · Sold 1.37M
Granted 632.8K · Sold 421.8K
Granted 476.3K · Sold 348.0K
Granted 39.9K · Sold 16.0K
Granted 5.2K · Sold 2.0K
Granted 63.1K · Sold 60.0K
Granted 71.9K · Sold 68.8K
Bought 4.5K
Granted 69.2K · Bought 1.2K · Sold 66.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lian BrianPresident & CEO, Director · 51 transactions | +18.3% | 2.60M | 2.22M | — | 1.37M |
| Mancini MariannaChief Operating Officer · 37 transactions | +36.3% | 409.2K | 632.8K | — | 421.8K |
| Zante GregChief Financial Officer · 47 transactions | +21.1% | 189.9K | 476.3K | — | 348.0K |
| Foehr Matthew WDirector · 4 transactions | +18.7% | 132.0K | 39.9K | — | 16.0K |
| Macartney LawsonDirector · 3 transactions | -20.1% | 51.1K | 5.2K | — | 2.0K |
| Rowland Charles A JrDirector · 5 transactions | +10.5% | 33.1K | 63.1K | — | 60.0K |
| Singleton J MatthewDirector · 17 transactions | +33.2% | 12.7K | 71.9K | — | 68.8K |
| Aubuchon Neil WilliamChief Commercial Officer · 1 transaction | — | 4.5K | — | 4.5K | — |
| Rouan Sarah KathrynDirector · 8 transactions | — | 4.4K | 69.2K | 1.2K | 66.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -2.35M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.